Dose-Response Relationship of Glucagon-like Peptide-1 Receptor Agonists on HbA1c and Body Weight in Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-Analysis.

Chen QQ, Yang Y, Xu JY, Wang J, Fang TY, Yuan Y, Wang C, Zhang L

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists3 Dec 2024Cited by 5 (Europe PMC)

PMID39638244DOI10.1016/j.eprac.2024.11.013PepBankPUB-39638244

Publisher page PubMedAsk about this study

Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

3 results from studies that gave the peptide. 3 results from people.

01HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, tirzepatide 10 mg/wk reduced HbA1c by 1.76% in a network meta-analysis.
In plain wordsIn adults with type 2 diabetes, tirzepatide at 10 mg a week lowered HbA1c, a blood sugar marker, in a pooled analysis.
Peptide
Tirzepatide
Outcome
DecreaseHbA1c change
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 mg/wkAs given in this study (human).
Measurements
HbA1c change
−1.76%
tirzepatide 10 mg/wk
Source sentences
Summary
Tirzepatide (10 mg/wk) was found to be particularly effective, reducing HbA1c by -1.76% (95% credible intervals: -2.10 to -1.41)
1 context sentence(design, population, supporting numbers)
Summary · context
Selected studies were randomized controlled trials focusing on adult T2DM patients treated with GLP-1 RAs.
Report a problemFND-3963824401
02HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, tirzepatide 10 mg/wk reduced body weight by 8.63 kg in a network meta-analysis.
In plain wordsIn adults with type 2 diabetes, tirzepatide at 10 mg a week lowered body weight in a pooled analysis.
Peptide
Tirzepatide
Outcome
DecreaseBody weight change
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
10 mg/wkAs given in this study (human).
Measurements
Body weight change
−8.63 kg
tirzepatide 10 mg/wk
Source sentences
Summary
body weight by -8.63 kg (95% credible intervals: -9.84 to -7.39)
1 context sentence(design, population, supporting numbers)
Summary · context
Selected studies were randomized controlled trials focusing on adult T2DM patients treated with GLP-1 RAs.
Report a problemFND-3963824402
03HumanSystematic reviewSafety outcome
In adults with type 2 diabetes, tirzepatide 10 mg/wk did not significantly increase adverse events in a network meta-analysis.
In plain wordsIn adults with type 2 diabetes, tirzepatide at 10 mg a week did not clearly raise side effects in a pooled analysis.
Peptide
Tirzepatide
Outcome
No significant changeAdverse events
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
10 mg/wkAs given in this study (human).
Source sentences
Summary
without a significant increase in adverse events, highlighting its optimal balance between efficacy and safety.
1 context sentence(design, population, supporting numbers)
Summary · context
Selected studies were randomized controlled trials focusing on adult T2DM patients treated with GLP-1 RAs.
Report a problemFND-3963824403

Studies that did not test the peptide alone2

In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Tirzepatide.

04HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, GLP-1 RAs as a class showed a nonlinear dose-response relationship with significant HbA1c reductions.
In plain wordsIn adults with type 2 diabetes, GLP-1 drugs as a group lowered HbA1c, with effects not rising in a straight line with dose.
Peptide
Tirzepatide
Outcome
DecreaseHbA1c reduction (pooled GLP-1 RAs, dose-response)
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
The study revealed a nonlinear dose-response relationship for various GLP-1 RAs, indicating significant reductions in HbA1c and body weight.
1 context sentence(design, population, supporting numbers)
Summary · context
Selected studies were randomized controlled trials focusing on adult T2DM patients treated with GLP-1 RAs.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3963824404
05HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, GLP-1 RAs as a class showed a nonlinear dose-response relationship with significant body weight reductions.
In plain wordsIn adults with type 2 diabetes, GLP-1 drugs as a group lowered body weight, with effects not rising in a straight line with dose.
Peptide
Tirzepatide
Outcome
DecreaseBody weight reduction (pooled GLP-1 RAs, dose-response)
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
The study revealed a nonlinear dose-response relationship for various GLP-1 RAs, indicating significant reductions in HbA1c and body weight.
1 context sentence(design, population, supporting numbers)
Summary · context
Selected studies were randomized controlled trials focusing on adult T2DM patients treated with GLP-1 RAs.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3963824405

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.